ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago.